
As part of its partnership, Shamir will provide insight and expertise for sales development, customer service, as well as research and development

As part of its partnership, Shamir will provide insight and expertise for sales development, customer service, as well as research and development

A comprehensive analysis of the possible directions corporate optical practices might be headed in.

Michael Brown, OD, MHS-CL, FAAO shares what he wishes he knew before starting his career in optometry.

Study evaluated twice-daily administration of VUITY (pilocarpine HCI ophthalmic solution) 1.25% in adults with age-related blurry near Vision

Live from Vision Expo East in New York, a look at Tura's new line of glasses: Glemaud.

Elevatum was created as a phase 4, multicenter, open-label, single-arm trial to specifically study Vabysmo (faricimab-svoa) in these underrepresented populations.

Sunlight in the classroom can be a protective measure against the development of myopia, researchers have found.

The partnership is in support of the company's latest dry eye relief campaign and part of the launch for its leading global artificial tear drop brand.

Fully recovered COVID-19 patients have a higher prevalence for developing dry eye disease, researchers report.

Shamir goes mobile, volunteering mobile laboratories to test and fit eyeglasses for Ukrainian refugees.

New research finds a drug used to treat alcohol use disorder could be a game-changer in restoring vision for patients with progressive blinding disorders.

At-home visual acuity tests compare favorably within 1 line of vision to VA measurements performed during a standard office visit.

See our latest poll results

Essilor reveals plans for the presbyopia space in addition to lens technologies

Live from Vision Expo East, Optometry Times' Diana Canto-Sims, OD speaks with EyeCarePro's Keyanna Ingram

Presbyopia awareness: Causes, risk factors, symptoms, correction options and market trends.

This latest approval for Beovu (brolucizumab) 6 mg is the second indication granted by the EC, as it was first approved in 2020 for the treatment of AMD.

Heru Chief Marketing Officer Brandon Barber speaks on the company's upcoming advancements and two new testing modalities on its diagnostic platform: Fast Pattern Suprathreshold Visual Field and the Farnsworth D-15 extended color vision exam.

In the Spring 2022 issue of Corporate Optometrist, Naheed Ahmad, OD is featured.

After 10 years, women’s median earnings are 9% less than men’s

Mark Dunbar, OD, FAAO, offers a look at what to expect from this year's high-sakes competition at Vision Expo East.

An exciting line-up of speakers and panelists is promised for the main-stage destination at VEE 2022.

Researchers report a recombinant biologic derived from blood-feeding ticks may be a potential treatment for allergic eye disease

Approved by the FDA last October, XIPERE (triamcinolone acetonide injectable suspension) was approved by the FDA last October as the first and only therapy for treating macular edema associated with uveitis.

US commercialization of EVO will begin immediately in select cities across the country.

Happy memories of an OD’s grandfather help defuse heated patient situation

Check out our latest poll!

The latest launches of BRIO-I and BRIO-II follow promising topline data from the phase 2 VIVD clinical study evaluating Brimochol PF.

The National Institute for Health and Care Excellences announced SLT as the new primary form of glaucoma intervention.

With its portable capabilities, the Heru platform replaces legacy diagnostic devices and surpasses standard care in cost and size.